Inhibitors targeting various components of this pathway, including PI3K inhibitors (e.g., idelalisib), AKT inhibitors (e.g., ipatasertib), and mTOR inhibitors (e.g., everolimus), have shown clinical efficacy in different cancer types.290 Due to the complexity and redundancy of the PI3K/AKT/mTOR network, combination therapies are being evaluated to overcome resistance mechanisms and improve therapeutic outcomes. The gene discussed is MTOR; the disease is cancer.